**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 85141

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of *TDO2* as a potential therapeutic target**

Wang R *et al*. Potential therapeutic target

Ru Wang, Yan-Mei Yang

**Ru Wang,** Henan University of Chinese Medicine, Collaborative Innovation Centre for Chinese Medicine and Respiratory Diseases, Zhengzhou 450046, Henan Province, China

**Yan-Mei Yang,** Zhengzhou University, Research Centre of Basic Medicine, Academy of Medical Sciences, Zhengzhou 450000, Henan Province, China

**Author contributions:** Yang YM designed the research study; Wang R and Yang YM performed the research; Yang YM analysed the data and wrote the manuscript; Wang R performed the experiment research; all authors have read and approved the final manuscript.

**Corresponding author: Yan-Mei Yang, PhD, Doctor,** Zhengzhou University, Research Centre of Basic Medicine, Academy of Medical Sciences, No. 40 North University Road, Erqi District, Zhengzhou 450000, Henan Province, China. yang\_yanmei@gs.zzu.edu.cn

**Received:** April 14, 2023

**Revised:** June 1, 2023

**Accepted:** June 13, 2023

**Published online:**

**Abstract**

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a high mortality rate. On this basis, exploring potential therapeutic targets to meet the unmet needs of IPF patients is important.

AIM

To explore novel hub genes for IPF therapy.

METHODS

Here, we used public datasets to identify differentially expressed genes between IPF patients and healthy donors. Potential targets were considered based on multiple bioinformatics analyses, especially the correlation between hub genes and carbon monoxide diffusing capacity of carbon monoxide, forced vital capacity, and patient survival rate. The mRNA levels of the hub genes were determined through quantitative real-time polymerase chain reaction.

RESULTS

We found that *TDO2* was upregulated in IPF patients and predicted poor prognosis. Surprisingly, single-cell RNA sequencing data analysis revealed significant enrichment of *TDO2* in alveolar fibroblasts, indicating that *TDO2* may participate in the regulation of proliferation and survival. Therefore, we verified the upregulated expression of *TDO2* in an experimental mouse model of transforming growth factor-β (TGF-β)-induced pulmonary fibrosis. Furthermore, the results showed that a *TDO2* inhibitor effectively suppressed TGF-β-induced fibroblast activation. These findings suggest that *TDO2* may be a potential target for IPF treatment. Based on transcription factors-microRNA prediction and scRNA-seq analysis, elevated *TDO2* promoted the IPF proliferation of fibroblasts and may be involved in the P53 pathway and aggravate ageing and persistent pulmonary fibrosis.

CONCLUSION

We provided new target genes prediction and proposed blocking TGF-β production as a potential treatment for IPF.

**Key Words:** Idiopathic pulmonary fibrosis; Lung function; Overall survival; Transforming growth factor-β; *TDO2* inhibitor

Wang R, Yang YM. Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of *TDO2* as a potential therapeutic target. *World J Cardiol* 2023; In press

**Core Tip:** This study is unique in several aspects: (1) We identified six hub genes for idiopathic pulmonary fibrosis (IPF) and determined through quantitative real-time polymerase chain reaction; (2) Multi-omics analysis proved that *TDO2* was upregulated in IPF patients and promoted the IPF proliferation of fibroblasts; (3) *TDO2* may be involved in P53 pathway and aggravate aging and persistent pulmonary fibrosis; and (4) *TDO2* inhibitor effectively suppressed transforming growth factor-β-induced fibroblast activation.

**INTRODUCTION**

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease characterized by exertional dyspnoea and diminished lung function. Its progression seriously affects the quality of life of patients, leading to respiratory failure and death in severe cases. In addition, IPF is a fatal disease characterized by abnormal lung epithelial cells and excessive accumulation of lung interstitial matrix[1]. Clinical symptoms are usually progressive and manifest as shortness of breath, dry cough, and dyspnoea. Smoking exacerbates the loss of lung function in patients with IPF[2]. In addition to smoking, other factors, including viral and bacterial infections, genetic factors, age and sex, have different effects on IPF patients[3–7]. IPF mainly occurs in male patients and may develop earlier in men than in women for various biological reasons[8]. In terms of age, IPF predominantly affects elderly individuals, and its prevalence increases with age[9]. These microinjuries induce abnormal epithelial-fibroblast communication[10,11]. Moreover, slight injuries induce matrix-producing myofibroblasts and the accumulation of extensive extracellular matrix (ECM) with remodelling in the lung interstitium[12].

The median annual survival after the diagnosis of IPF is 2 to 3 years[13]. Although two antifibrotic drugs (pirfenidone and nintedanib) are currently available, they can only slow the progression of the disease instead of curing IPF[14]. There is no effective treatment for the illness, and a major need for new therapies has not been satisfied[15]. Therefore, identifying and intervening in key genes of IPF and exploring new therapeutic approaches are essential. The diagnosis of IPF usually requires respiratory physicians, radiologists, and pathologists to review various clinical features, imaging results, and biopsy results of patients in a group discussion to arrive at the final diagnosis. Standard imaging assessment of IPF with high-resolution computed tomography provides diagnostic and predictive information[16]. The degree of fibrosis and cellularity correlated with forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO), as well as predicted mortality, can be observed. The most common indicators of lung function associated with prognosis are total vital capacity, FVC, and DLCO[17,18]. The decreases in FVC and DLCO in IPF patients reflect disease progression and predict mortality[19,20].

Previous studies on IPF still need to be extended, and further identification of additional gene-targeted therapies for IPF remains challenging. In this study, several novel genes were investigated to explore the treatment of IPF. We adopted quantitative real-time polymerase chain reaction (qRT-PCR) to identify common hub genes in multiple sets of IPF data and discussed the correlation between these genes and lung function and the overall survival rate. Afterwards, a hub gene, *TDO2*, was used as an example to demonstrate the expression level. This gene was increased in IPF and validated by western blotting. After inhibitor treatment, transforming growth factor-β (TGF-β)-induced fibroblast activation was effectively inhibited.

**MATERIALS AND METHODS**

***Data collection and preprocessing***

All raw data in this study were retrieved from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). GSE53845 (platform: Agilent microarray GPL6480) consists of lung tissues from 8 healthy subjects and 40 IPF patients[21]. In GSE47460[22], only samples with IPF from the interstitial lung disease population were included. The Agilent GPL14550 platform consists of 91 normal and 122 IPF samples, and the Agilent GPL6480 platform consists of 17 normal and 38 IPF samples. There were 110 men and 50 women with IPF, of whom 58 had never smoked, 96 had smoked, 2 were current smokers and 4 had an unclear smoking status. The age range of individuals with these IPF data was 37 to 82 years. GSE24206 (platform: Affymetrix GPL570) consists of 6 healthy and 17 IPF samples[23]. GSE110147 (platform: Affymetrix GPL6244) consists of 11 normal and 22 IPF samples[24]. The GEOquery package[25] was used to download the series matrix files of the databases above in R (v4.0.2). Soft formatted family files were downloaded to correctly map the probe ID to the gene symbol. GSE136831 contains lung tissue from 32 IPF and 28 control patients.

***Differentially expressed gene screening***

We screened differentially expressed genes (DEGs) between IPF patients and controls using the R package of the Microarray Data Linear Model (limma, version 3.50.3)[26]. The significant DEGs were identified according to the thresholds of adjusted *P* < 0.05 and fold change (FC) > 1.5. The common DEGs in the datasets were visualized by ggVennDiagram[27].

***Functional and pathway enrichment analyses***

Gene Ontology (GO) enrichment analyses of hub genes were performed by the clusterProfiler package with a background set of all Entrez IDs mapped to a GO pathway[28]. There are three functional categories, specifically biological processes (BPs), cell components (CCs), and molecular functions (MFs). Because GO is organized in a parent-child structure, a parent term can have a large percentage of overlap with its child terms. Concerning this problem, a simplified approach in the clusterProfiler implements was used. The organism reference was set as “org.Hs.eg.db”. The terms meeting *P* < 0.05, *p*AdjustMethod = "BH" and *P*adjust < 0.05 were selected. Enrichment analyses of the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome were performed using Database for Annotation, Visualization and Integrated Discovery (DAVID)[29]. After Benjamini-Hochberg adjustment, terms meeting *P* < 0.01 were selected.

***Protein-protein interaction network establishment and hub gene exploration***

The protein-protein interaction (PPI) network of identified DEGs was built using the Search Tool for the Retrieval of Interacting Genes (STRING, https://string-db.org, v11.5) to determine the functional interactions between the products of the key genes. The condition for constructing the PPI network was an interaction combined score > 0.4. The interaction information network was downloaded and visualized through Cytoscape software (v3.9.1). The Molecular Complex Detection (MCODE) plugin was applied to select the significant subnetworks from the PPI network (degree cut-off ≥ 2, node score cut-off ≥ 0.2, K-core ≥ 2, and max depth = 100, score ≥ 3)[30]. The hub genes were identified through a plugin from Cytoscape named cytoHubba[31]. The cytoHubba plugin quantifies the importance of nodes in biological interaction networks through 11 node ranking methods. Five of these methods were adopted in this study: Degree, maximum neighbourhood component (MNC), density of maximum neighbourhood component (DMNC), maximal clique centrality (MCC), and edge percolated component (EPC). The top 30 Hubba nodes were ranked by these methods, and common hub genes were taken as the true final hub genes.

***Overall survival analyses***

Disease status, survival days, age, and survival status were extracted from GSE70866[32]. Clinical data from 176 IPF-diagnosed cases were used to analyse survival changes in specific genes in IPF. According to the mRNA expression from one of the hub genes, IPF patients were divided into high-expression (upper tertile) and low-expression (lower tertile) groups. The survival analysis of hub genes was performed in R using the functions “survfit” and “coxph” of the “survival” package. Survival curves were generated using the “ggsurvplot” function of the “survminer” package. The final results were visualized by ggplot2[33].

***Clinical correlation***

Several factors, including age, sex, smoking history, carbon monoxide diffusion capacity (DLCO), and FVC, have been identified as predictors of poor survival in IPF patients[34]. Varying degrees of decline in FVC and DLCO predict higher mortality in patients with IPF[35]. In this study, clinical metadata were analysed using clinical datasets of GEO accession No. GSE47460[22]. Linear models were created for selected gene expression and clinical variables such as DLCO and FVC percentage using the lm function in the R stats package. Scatterplots were made using the ggscatter function in the ggpubr package. The Pearson correlation coefficient and significance were calculated in R using the stat\_cor function in the ggpubr package.

***Prediction of target microRNAs***

We used three online microRNA (miRNA) databases (miRWalk, DIANATools, and miRDB) to predict miRNAs of hub genes with the default parameters. The miRNA was selected if it targeted a gene in all three databases. Subsequently, Cytoscape was used to construct the mRNA-miRNA coexpression network.

***Transcription factors-miRNA prediction***

Both miRNAs and transcription factors (TFs) are important in gene transcription and expression. Thus, clarifying the regulatory relationship between miRNAs and mRNAs and discovering key TFs can provide more insight into the pathological mechanisms of IPF. The "Enrichment analysis" module in TransmiR v2.0[36] was used to identify significant TFs that may regulate the list of miRNAs targeting TDO2.

***Mouse model of Bleomycin-induced pulmonary fibrosis***

SPF C57/6J mice were purchased from Beijing Weitonglihua Experimental Animal Co., Ltd. This experiment was approved by the Experimental Animal Welfare Ethics Review Committee of Henan University of Traditional Chinese Medicine (Review No. DWLL202110014). Mice were fed for one week in an SPF barrier environment in the Animal Experimental Center of Henan University of Chinese Medicine. Mice were randomly divided into two groups. For the phosphate-buffered saline (PBS) group, mice were intratracheally administered 50 μL of saline at Day 0. All mice were subjected to an anaesthesia experiment with a small animal anaesthesia machine (Ruiwode Life Technology Co., Ltd., Shenzhen, China). The light source was fixed at the pharyngeal skin, and the surgical instrument was fully exposed to the pharynx. At this time, a bright spot could be observed to open and close continuously with the spontaneous respiration of mice, and a tracheal intubation was inserted into the bright spot. For the Bleo group, mice were given intratracheal instillation of 50 μL of bleomycin (5 mg/kg). On Day 21, mice were euthanized by intraperitoneal injection of excessive pentobarbital sodium. Lung tissue was homogenized in TRIzol (Invitrogen) and stored at -80 °C for subsequent RNA isolation.

***Cell culture and treatment***

TheA549 cell line and IMR-90 cell line were purchased from ATCC. A549 cells were cultured in F-12K medium (Boster Biological Technology) containing 10% foetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. IMR-90 cells were cultured in DMEM (Biological Industries) containing 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. The MLE-12 cell line was purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). MLE-12 cells were cultured in DMEM/F-12 medium (Corning) containing 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. A549, MLE-12, and IMR-90 cells were incubated in a humidified incubator with 95% air and 5% CO2 at 37 °C. A549 cells, MLE-12 cells, and IMR-90 cells were seeded in six-well plates and cultured overnight. Cells were treated with TGF-β (10 ng/mL) for 24 h[37] and then exposed to 680C91 (20 μm) for 24 h.

***Quantitative real-time polymerase chain reaction assay***

Primers were designed using PrimerBank (https://pga.mgh.harvard.edu/primerbank/index.html) and synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). Total RNA was extracted using RNAiso Plus (TaKaRa) according to the manufacturer’s instructions. Reverse transcription (RT) was performed using HiScript® II Q RT SuperMix for qPCR (Vazyme, Nanjing, China). The reactions were performed using a QuantStudio 6 real-time fluorescence quantitative PCR System (Life Technologies, Singapore). The procedure was detailed as follows: Lung tissue was homogenized on ice with TRIzol. After complete homogenization, the homogenized solution was allowed to settle at room temperature for 5 min. The homogenate was then mixed with 200 μl/mL chloroform, allowed to stand at room temperature for 3 min and then centrifuged at 12000 × *g* for 15 min at 4 °C to separate the phases. The aqueous RNA phase was removed and dispensed into a new 2 mL microcentrifuge tube. The upper aqueous phase (RNA solution) was transferred to a new EP tube, mixed with isopropyl alcohol equal to the supernatant, and placed at 12000 × *g* for 10 min at 4 °C, and the supernatant was discarded. Then, 75% ethanol was added to 1 mL/mL TRIzol and gently shocked at 4 °C and 12000 × *g* for 10 min, and the supernatant was discarded. The pellets were allowed to air dry for approximately 5 min and then dissolved in DEPC water to measure the RNA concentration. The TOYOBO ReverTra Ace qPCR RT Kit was used for RT. RNA was incubated for 10 min at 65 °C and immediately placed on ice. The RT reaction contained 1 μg of RNA, 2 μL of 5 × RT Buffer, 0.5 μL of RT Enzyme Mix, 0.5 μL of Primer Mix, and up to 10 μL of DEPC water and was subsequently incubated at 37 °C for 15 min and 98 °C for 5 min. The values of the target genes were normalized using the 2−ΔΔCT method with the values of the housekeeping gene 18S. Technical repeats were performed three times. Notably, all mRNA levels are expressed as the mean ± SD.

***Western blot assay***

After treatment with TGF-β and 680C91, cells were lysed with RIPA buffer in ice. Protein samples of equal concentrations were separated using a 10% SDS-PAGE gel and electrotransferred onto PVDF membranes. Membranes with proteins were blocked with 5% skim milk, followed by incubation with primary and secondary antibodies. *TDO2* (Cat No.:15880-1-AP), α-smooth muscle actin (α-SMA) (Cat No.:14395-1-AP), COL-I (Cat No.:14695-1-AP), and GAPDH (Cat No.:10494-1-AP) were detected using the Bio-Rad Imaging System. These antibodies were purchased from Proteintech Group, Inc.

***Statistical analysis***

Independent-samples t tests were performed using SPSS 22.0 (IBM Corporation, Armonk, NY, United States), and *P* < 0.05 was considered significant. Pearson’s correlation coefficient r was calculated using the R function stat\_cor.

**RESULTS**

***Identification and enrichment analysis of DEGs***

Four sets of raw GEO data (GSE53845, GSE47460, GSE24206, and GSE110147) from five platforms were used to analyze the DEGs between the normal and IPF groups. Data sources are summarized in Supplementary Table 1. After background correction and data standardization, DEGs were determined between IPF and normal lung tissues. DEG analysis was performed by the R package “limma”. Based on the threshold of adjusted *P* < 0.05 and FC > 1.5, 2157 DEGs were identified in GSE53845, 2861 DEGs were screened out from GSE47460 under the GPL6480 platform, 2113 DEGs were obtained in GSE47460 under the GPL14550 platform, 2525 DEGs were detected in GSE24206, and 7146 DEGs were selected in GSE110147. Venn analysis showed that the DEGs of GSE110147 had less than 50% consistency with other datasets (Supplementary Figure 1). Therefore, GSE110147 was discarded in subsequent analyses. A total of 254 common genes were screened by intersecting the remaining four DEG datasets (Figure 1A).

The biological roles and functional pathways of the 254 DEGs were revealed by GO enrichment analysis. The three functional categories were BPs (Figure 1B), CCs (Figure 1C), and MFs (Figure 1D). The results showed that DEGs were significantly involved in “extracellular matrix organization”, “response to transforming growth factor beta”, “regulation of insulin-like growth factor receptor signalling pathway”, “regulation of neuron maturation”, “collagen-containing extracellular matrix”, “extracellular matrix structural constituent”, “serine-type endopeptidase activity”, “calcium-activated potassium channel activity”, and “Wnt-protein binding”. The results of the KEGG and Reactome pathway analyses (Figure 1E) identified by DAVID showed that the DEGs were significantly correlated with “extracellular matrix organization”, “collagen degradation”, “regulation of insulin-like growth factor transport and uptake by insulin-like growth factor proteins”, and “molecules associated with elastic fibres”.

***PPI network analysis and identified hub genes***

For further elucidation of the interaction of common DEGs, interaction networks were constructed using STRING (STRING v11.5, https://string-db.org/). The TSV file containing information on PPI network interactions was downloaded and visualized by Cytoscape (V3.9.1). The network included 69 nodes and 59 edges, with an average number of neighbours of 2.0. The MCODE plugin in Cytoscape was used to detect the most significant hub gene modules and cluster scores under the default parameters. Three modules were identified with the MCODE plugin (Supplementary Figure 2) according to the following filter criteria: Cluster 1 (score: 4.000, 4 nodes and 6 edges), Cluster 2 (score: 4.000, 4 nodes and 6 edges), and Cluster 3 (score: 3.000, 3 nodes, and 3 edges). Afterwards, five algorithms (MCC, DMNC, MNC, Degree, and EPC) were used to identify hub genes in the cytoHubba plugin (Figure 2A-E). The top 30 genes in each algorithm were considered hub genes (Supplementary Tables 2-6). Finally, 15 genes were detected in all five algorithms: *RET*, *TGFB3*, *HSD17B6*, *SULF1*, *ASPN*, *SDR16C5*, *ALDH1A3*, *COL3A1*, *COL1A2*, *KCNMA1*, *COL5A2*, *KCNMB4*, *AOX1*, *KCNN3*, and *KCNN4* (Figure 2F).

***Correlation between gene expression and lung functions***

The above analysis showed significant enrichment of genes in epithelial cell proliferation. We expect a variety of candidate targets that can be used to treat IPF. Combined with the results of GO molecular functional enrichment analysis, these findings showed that tryptophan 2,3-dioxygenase activity and amino acid binding were significantly enriched (*P* < 0.05), and TDO2 was involved in these pathways. Figure 1D does not show this pathway because it was not ranked high enough. Moreover, in conjunction with the query results from DGIdb (https://dgidb.org/search\_categories), which indicated that *TDO2* has a potential drug effect, these data were added to the downstream analysis. Moreover, *TDO2* has been confirmed to promote tumour cell proliferation and differentiation in the progression of oesophageal squamous cell carcinoma[38]. No relevant studies have been reported on the role of *TDO2* in IPF. Therefore, 15 genes identified by PPI and *TDO2* were included in the subsequent analysis.

The potential role of these genes in IPF development was examined by tracking expression changes in public datasets. We used linear models to assess changes in gene expression and lung function. The results showed that changes in 16 genes were directly associated with lung function. Twelve (*TDO2*, *RET*, *TGFB3*, *SULF1*, *ASPN*, *ALDH1A3*, *COL3A1*, *COL1A2*, *KCNMA1*, *COL5A2*, *KCNN3*, *KCNN4*) of the 16 genes were upregulated in IPF patients in all datasets. Additionally, these 12 genes significantly decreased in terms of lung function (decrease in DLCO and FVC, as shown in Figure 3A-L and Supplementary Figure 3A-L respectively). The changes in *AOX1* expression were conflicting. We observed a downregulation in IPF in the GSE53845 and GSE24206 data (logFC of -0.94 and logFC of -1.27, respectively) and an upregulation in IPF in the GSE47460 data (logFC of 0.9). Therefore, although *AOX1* is negatively correlated with DLCO and FVC (Figure 3M and Supplementary Figure 3M), we have excluded this gene from the subsequent analysis. Three (*HSD17B6*, *SDR16C5*, *KCNMB4*) of 16 genes were downregulated in IPF patients in all datasets, revealing a decrease in lung function (decreased DLCO and FVC, as shown in Figure 3N-P and Supplementary Figure 3N-P respectively).

***Survival analysis***

To explore the prognostic value of hub genes in IPF, we performed a survival analysis by Cox models. The data were from GSE70866[32]. Sample grouping information and the average expression and difference statistics of hub genes in each group are shown in Table 1. Survival analysis showed that *TDO2*, *HSD17B6*, *SULF1*, *SDR16C5*, *COL3A1*, *KCNMA1*, *KCNMB4*, *KCNN4*, and *ALDH1A3* were independent prognostic factors for poor survival in IPF (Figure 4). Patients with high expression of these genes are likely to suffer unfavourable outcomes. There was no significant difference between the expression of other hub genes and survival in IPF patients.

***Validation of hub gene expression by qRT-PCR***

The mRNA expression levels of the hub genes associated with low survival rates were detected through qRT-PCR. The sequences of the primers are shown in Table 1. The results showed that the mRNA expression levels of six genes (*TDO2*, *COL3A1*, *KCNN4*, *SULF1*, *KCNMA1*, *ALDH1A3*) were significantly increased in the bleomycin-induced pulmonary fibrosis group compared with the control group (*P* < 0.01, Figure 5). The direction of gene dysregulation was consistent with the test data analysis. These results demonstrate the validity of these genes for further analysis.

***Prediction of target miRNAs and identifying genes of interest***

Previous studies have shown that miRNAs are widely involved in disease regulation by targeting key genes[39]. The typical function of miRNAs is to bind to their 3′ untranslated regions to regulate various target genes. TFs can upregulate or downregulate miRNAs, corresponding to positive and negative feedback phenomena. Identification of the TF-miRNA-mRNA coregulatory network can help determine which miRNAs play a crucial role in the pathogenesis of hub genes involved in IPF and how they interact with TFs to regulate IPF-related genes. We used three online miRNA databases (miRWalk, DIANATools, and miRDB) to predict miRNAs targeting the above nine hub genes. The targeted miRNA was selected when it targeted a gene in all three databases. Finally, 367 miRNAs were selected, and 401 mRNA-miRNA pairs were obtained (Supplementary Table 7). The interaction network of mRNAs and miRNAs, comprising 376 nodes and 401 edges, was constructed by Cytoscape (Supplementary Figure 4). Finally, TDO2 was selected to further explore the regulatory network.

TFs and miRNAs regulate each other to form feed-forward loops or feedback loops, where a TF regulates a miRNA or a miRNA inhibits a TF[40,41]. In this study, TransmiR was adopted to predict a list of significant TFs that may regulate miRNAs, and it provided 3730 highly reliable TF-miRNA regulations[36]. TDO2 was regulated by seven miRNAs (hsa-let-7g, hsa-mir-6878, hsa-mir-4270, hsa-mir-4441, hsa-mir-7974, hsa-let-7a-2, hsa-mir-6754). Based on the TFs in TransmiR prediction with a threshold of *P* < 0.05, the number of targeted miRNAs for regulation was 7. Nine molecules corresponding to this condition were *TCF12*, *SPI1*, *HIF1A*, *RUNX1*, ETS-related gene (ERG), *MYC*, *EP300*, *RELA*, and *STAT1*. On this basis, the TF-miRNA-mRNA network of *TDO2* was constructed by Cytoscape (Figure 6).

***TDO2 in IPF and alveolar fibroblasts***

*TDO2* was upregulated in IPF in all trained datasets, as shown in Figure 7A. *TDO2* expression was upregulated in IPF, while lung function was decreased (decreased DLCO and FVC, Figure 7B and C and Supplementary Figure 5A). In addition, single-cell RNA-seq data containing 32 IPF and 28 control lung tissues (GSE136831)[42] were used to validate *TDO2* expression between IPF and normal lung tissues of patients. The parameters and cell type identification in UMAP were consistent with those in a study of CD38-mediated pulmonary fibrosis[42]. In addition, *TDO2* expression was significantly enriched in alveolar fibroblasts (Figure 7D-F). This result is consistent with the proliferation of fibroblasts and myofibroblast accumulation in IPF. The above results were also supported by GSE135893 and GSE122960 (Supplementary Figure 5B-E). A UMAP plot with cells labeled by disease identity in GSE136831 has been added to Supplementary Figure 5F.

***Reduction of TGF-β-induced fibrosis by TDO2 deficiency***

To identify the effect of altered *TDO2* gene expression on fibrosis, we treated cells with *TDO2* inhibitors. Cells treated with TGF-β were the pulmonary fibrosis model group. After 24 h of TGF-β treatment, cells were treated with the *TDO2* inhibitor 680c91 to explore fibrotic changes. The same experiments were performed in three cell lines, including fibroblasts (IMR-90) and epithelial cells (A549 and MLE-12). The attenuated fibrosis was supported by the decrease in α-SMA and COL-I expression (Figure 8). These *in vitro* data reveal that decreased *TDO2* expression inhibited TGF-β-induced fibroblast activation, indicating that *TDO2* is a potential therapeutic target for fibrosis.

**DISCUSSION**

The progression of IPF seriously affects the lives of patients, while effective treatments are limited. To address the shortage of IPF-targeted therapeutic candidate genes, this study collected four sets of GEO public data to find common DEGs between IPF and normal lung tissues. Information on the common DEGs has been added to Supplementary Table 8. Since screening large public data ensures more accurate and generally applicable hub genes, data containing extensive IPF and control samples were selected for screening. For more robust data results, further screening was performed with clinical lung function indicators and survival analyses. Based on the PPI network and five cytoHubba algorithms, 15 hub genes were identified for the analysis. The relationship of these genes with lung function (such as DLCO and FVC) and overall survival was examined. Nine genes (*TDO2*, *HSD17B6*, *SULF1*, *SDR16C5*, *COL3A1*, *KCNMA1*, *KCNMB4*, *KCNN4*, and *ALDH1A3*) significantly decreased lung function in IPF and caused poor survival. The selected genes were validated by scRNA-seq data, qRT-PCR and western blotting in three cell lines, indicating these results are consistent with the actual situation. Compared with the validation in a single cell line, the results in multiple cell lines provide better support for the therapeutic function of *TDO2* inhibitors.

GO analysis showed that the common DEGs were primarily enriched in extracellular matrix organization (BP), collagen-containing extracellular matrix (CC), and extracellular structure constituent (MF). These biological pathways are involved in the degradation, regeneration, and remodelling of fibrosis[43]. IPF is the most common idiopathic interstitial pneumonia. However, nothing, other than a lung transplant, has thus far increased survival[44]. The antifibrotic drugs on the market are pirfenidone and nintedanib, which are used to slow the progression of the disease. Thus, further exploration of other therapeutic drugs is warranted. Among the screened genes, *SULF1* promotes histone H4 acetylation, enhances the effects of HDAC inhibitors, and inhibits tumorigenesis in hepatocellular carcinoma[45]. HDAC inhibitors can downregulate *COL3A1* expression in primary IPF lung fibroblasts[46]. Therefore, targeting histone deacetylases in IPF may also be a future therapeutic approach[15].

MiRNAs are endogenous noncoding RNAs with regulatory functions and a length of approximately 22 nt[47]. These molecules play important roles in regulating the expression of genes related to the growth and development of organisms and the occurrence of diseases. Studies have shown that each miRNA may have dozens or hundreds of target genes[48]. With the continuous discovery of specific miRNAs, the study of target genes in some disease pathways may lead to the discovery of new therapeutic methods. In this study, a regulatory pathway that may have the potential to regulate the expression of *TDO2* was identified through the TF-miRNA-mRNA network. In this way, the underlying molecular mechanisms of IPF were revealed, providing potential targets for developing new therapeutic agents to treat IPF patients. The results showed nine TFs targeting seven miRNAs to coregulate *TDO2*. Among them, HIF1A induced overexpression of the p53/hypoxia pathway in the tissues of IPF patients[49]; EP300 was highly enriched at enhancers of several genes in multiple profibrotic pathways[50]; immunostaining of RELA (v-rel reticuloendotheliosis viral oncogene homologue A) was increased in type 2 alveolar epithelial cells of mice treated with bleomycin[51]. The function of the TF ERG is dysregulated in ageing. A previous study showed that ERG dysfunction exacerbated pulmonary vascular ageing and persistent fibrosis[52]. We speculated that the disorder of ERG caused positive feedback, such as mechanisms involving miR-4270 and miR-4441 to regulate the expression of *TDO2*, so specific inhibition of ERG could be assessed in follow-up research, and combined treatment may be the future direction of pulmonary fibrosis treatment.

This study also has some limitations. We used five common sets from IPF data, but the intersection of common DEGs between one group of datasets (GSE110147) and the other groups was less than 50%. This group was removed in subsequent analysis, and the DEGs in the remaining groups were screened using thresholds of adjusted *P* < 0.05 and FC > 1.5. The selected common DEGs had identical direction of dysregulation, indicating that the validity of the thresholds and the data are reasonable. With the progress of scientific research, more IPF-related data can be generated, and additional datasets or novel computing methods can be adopted to find relevant genes affecting IPF. In addition to human lung tissue data, mouse data can be analysed and verified. With the diversification of sequencing technologies, multiomics data analysis can be adopted to validate genes. For example, single-cell RNA sequencing technology can examine the expression of specific genes in different cell populations and the existence of tissue preferences. Some genes were differentially expressed in at least one cell type, while some genes related to ECM were largely expressed in fibroblast subpopulations[53]. By investigating the expression of *TDO2* in each cell cluster in scRNA-seq data (GEO series accession No. GSE135893 and GSE122960[54]), we found higher expression in fibroblasts than in other cell clusters. The specific mechanism of *TDO2* in fibroblasts should be further investigated.

Moreover, when using STRING to construct PPI networks, we used different interaction score thresholds to obtain different network structures. Important candidate genes in common DEGs might be missed, and these genes would not appear in the network due to insufficient research. We reviewed these genes again and found that *TDO2* has potential drug effects. Previous research has shown that *TDO2* knockdown inhibits colorectal cancer progression[55]. In vitro experiments have shown that knocking down or blocking *TDO2* expression in myofibroblast subsets can effectively reverse T-cell immunosuppression in oral squamous cell carcinoma[56]. No relevant studies have been reported on the role of *TDO2* in IPF. Therefore, we included *TDO2* for follow-up analysis. Fortunately, the results of the network analysis in this study validated independent data from public databases and qRT-PCR data from our laboratory. However, the disadvantage is that we performed the experiment once, and there is a lack of repeated experiments to prove the repeatability of these findings. Additionally, it is important to explore whether the other group receiving more or less bleomycin has any effect on the reproducibility of the results. Representative images of rat body weight, survival rate, lung wet-to-dry weight ratio, lung hydroxyproline content, mouse hematoxylin and eosin staining and Masson’s trichrome staining of lung sections are more conducive to increasing the persuasiveness of our results, which will be further studied in the future. In summary, we demonstrated that the *TDO2* gene is significantly upregulated after bleomycin treatment and proposed blocking TGF-β production as a potential treatment for IPF. A more comprehensive study of *TDO2* in animal models would be worthwhile.

**CONCLUSION**

This study identified novel hub genes to explore the treatment of IPF, examined the upregulated expression of *TDO2*, and investigated the TF-miRNA-gene regulatory network of *TDO2*. After inhibitor treatment, TGF-β-induced fibroblast activation was effectively inhibited. *TDO2* appears to be an effective treatment for IPF. Therefore, the molecular mechanisms of these TFs and *TDO2* deserve further exploration. The findings provide new target gene prediction, and we propose blocking TGF-β production as a potential treatment for IPF.

**ARTICLE HIGHLIGHTS**

***Research background***

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with high mortality rate. Therefore, exploring potential therapeutic targets to meet the unmet needs of IPF patients is of great significance.

***Research motivation***

To explore potential targets for IPF treatment, as well as potential pathways and therapeutic methods.

***Research objectives***

Explore novel hub genes for IPF therapy. Whether *TDO2* can be a therapeutic target for IPF.

***Research methods***

We used public datasets (GSE53845, GSE47460, GSE24206, and GSE110147) to identify differentially expressed genes between IPF patients and healthy donors. Potential targets were considered based on multiple bioinformatics conditions, especially the correlation between hub genes and carbon monoxide diffusing capacity, forced vital capacity, and patient survival rate. The mRNA levels of the hub genes were determined through quantitative real-time polymerase chain reaction. Transforming growth factor-β (TGF-β) induced pulmonary fibrosis mouse model and the expression of *TDO2* was observed before and after the addition of inhibitor.

***Research results***

This study identifies novel hub genes to explore for IPF treatment. *TDO2* was upregulated in an experimental mouse model of TGF-β-induced pulmonary fibrosis and a *TDO2* inhibitor effectively suppressed TGF-β-induced fibroblast activation.

***Research conclusions***

*TDO2* could be a potential target for treatment of IPF.

***Research perspectives***

More complete work with animal models is needed, as the *TDO2* gene is apparently upregulated by bleomycin treatment.

**REFERENCES**

1 **Liang J**, Zhang Y, Xie T, Liu N, Chen H, Geng Y, Kurkciyan A, Mena JM, Stripp BR, Jiang D, Noble PW. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. *Nat Med* 2016; **22**: 1285-1293 [PMID: 27694932 DOI: 10.1038/nm.4192]

2 **Oh CK**, Murray LA, Molfino NA. Smoking and idiopathic pulmonary fibrosis. *Pulm Med* 2012; **2012**: 808260 [PMID: 22448328 DOI: 10.1155/2012/808260]

3 **Steele MP**, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA 3rd, Sporn TA, McAdams HP, Schwarz MI, Schwartz DA. Clinical and pathologic features of familial interstitial pneumonia. *Am J Respir Crit Care Med* 2005; **172**: 1146-1152 [PMID: 16109978 DOI: 10.1164/rccm.200408-1104OC]

4 **Han MK**, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J, Colby TV, Travis WD, Kazerooni EA, Gross BH, Martinez FJ. Sex differences in physiological progression of idiopathic pulmonary fibrosis. *Eur Respir J* 2008; **31**: 1183-1188 [PMID: 18321929 DOI: 10.1183/09031936.00165207]

5 **Chung JH**, Chawla A, Peljto AL, Cool CD, Groshong SD, Talbert JL, McKean DF, Brown KK, Fingerlin TE, Schwarz MI, Schwartz DA, Lynch DA. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. *Chest* 2015; **147**: 450-459 [PMID: 25317858 DOI: 10.1378/chest.14-0976]

6 **Stuart BD**, Choi J, Zaidi S, Xing C, Holohan B, Chen R, Choi M, Dharwadkar P, Torres F, Girod CE, Weissler J, Fitzgerald J, Kershaw C, Klesney-Tait J, Mageto Y, Shay JW, Ji W, Bilguvar K, Mane S, Lifton RP, Garcia CK. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. *Nat Genet* 2015; **47**: 512-517 [PMID: 25848748 DOI: 10.1038/ng.3278]

7 **Rangarajan S**, Bone NB, Zmijewska AA, Jiang S, Park DW, Bernard K, Locy ML, Ravi S, Deshane J, Mannon RB, Abraham E, Darley-Usmar V, Thannickal VJ, Zmijewski JW. Metformin reverses established lung fibrosis in a bleomycin model. *Nat Med* 2018; **24**: 1121-1127 [PMID: 29967351 DOI: 10.1038/s41591-018-0087-6]

8 **Sesé L**, Nunes H, Cottin V, Israel-Biet D, Crestani B, Guillot-Dudoret S, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Hirschi S, Dury S, Giraud V, Gondouin A, Bonniaud P, Traclet J, Juvin K, Borie R, Carton Z, Freynet O, Gille T, Planès C, Valeyre D, Uzunhan Y. Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal? *Front Med (Lausanne)* 2021; **8**: 713698 [PMID: 34422868 DOI: 10.3389/fmed.2021.713698]

9 **Strieter RM**, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. *J Clin Invest* 2007; **117**: 549-556 [PMID: 17332882 DOI: 10.1172/JCI30562]

10 **Brody AR**, Craighead JE. Interstitial associations of cells lining air spaces in human pulmonary fibrosis. *Virchows Arch A Pathol Anat Histol* 1976; **372**: 39-49 [PMID: 827082 DOI: 10.1007/BF00429715]

11 **Brody AR**, Soler P, Basset F, Haschek WM, Witschi H. Epithelial-mesenchymal associations of cells in human pulmonary fibrosis and in BHT-oxygen-induced fibrosis in mice. *Exp Lung Res* 1981; **2**: 207-220 [PMID: 7297522 DOI: 10.3109/01902148109052316]

12 **Rock JR**, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. *Proc Natl Acad Sci U S A* 2011; **108**: E1475-E1483 [PMID: 22123957 DOI: 10.1073/pnas.1117988108]

13 **Molyneaux PL**, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, Cookson WO, Maher TM, Moffatt MF. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2014; **190**: 906-913 [PMID: 25184687 DOI: 10.1164/rccm.201403-0541OC]

14 **Somogyi V**, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? *Eur Respir Rev* 2019; **28** [PMID: 31484664 DOI: 10.1183/16000617.0021-2019]

15 **Korfei M**, Mahavadi P, Guenther A. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. *Cells* 2022; **11** [PMID: 35626663 DOI: 10.3390/cells11101626]

16 **Fell CD**, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, Gross BH, Myers J, Travis WD, Colby TV, Toews GB, Flaherty KR. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2010; **181**: 832-837 [PMID: 20056903 DOI: 10.1164/rccm.200906-0959OC]

17 **Driesen P**, Lambrechts M, Kraaij K, Soldatenkova V, Chouaki N, Colinet B. A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. *Ther Adv Med Oncol* 2013; **5**: 159-168 [PMID: 23634194 DOI: 10.1177/1758834013481021]

18 **Kim DH**, Beckett JD, Nagpal V, Seman-Senderos MA, Gould RA, Creamer TJ, MacFarlane EG, Chen Y, Bedja D, Butcher JT, Mitzner W, Rouf R, Hata S, Warren DS, Dietz HC. Calpain 9 as a therapeutic target in TGFβ-induced mesenchymal transition and fibrosis. *Sci Transl Med* 2019; **11** [PMID: 31316008 DOI: 10.1126/scitranslmed.aau2814]

19 **Kolb M**, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. *Thorax* 2017; **72**: 340-346 [PMID: 27672117 DOI: 10.1136/thoraxjnl-2016-208710]

20 **Chung MP**, Park MS, Oh IJ, Lee HB, Kim YW, Park JS, Uh ST, Kim YS, Jegal Y, Song JW. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. *Adv Ther* 2020; **37**: 2303-2316 [PMID: 32297284 DOI: 10.1007/s12325-020-01328-8]

21 **DePianto DJ**, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ, Arron JR. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. *Thorax* 2015; **70**: 48-56 [PMID: 25217476 DOI: 10.1136/thoraxjnl-2013-204596]

22 **Peng X**, Moore M, Mathur A, Zhou Y, Sun H, Gan Y, Herazo-Maya JD, Kaminski N, Hu X, Pan H, Ryu C, Osafo-Addo A, Homer RJ, Feghali-Bostwick C, Fares WH, Gulati M, Hu B, Lee CG, Elias JA, Herzog EL. Plexin C1 deficiency permits synaptotagmin 7-mediated macrophage migration and enhances mammalian lung fibrosis. *FASEB J* 2016; **30**: 4056-4070 [PMID: 27609773 DOI: 10.1096/fj.201600373R]

23 **Meltzer EB**, Barry WT, D'Amico TA, Davis RD, Lin SS, Onaitis MW, Morrison LD, Sporn TA, Steele MP, Noble PW. Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle. *BMC Med Genomics* 2011; **4**: 70 [PMID: 21974901 DOI: 10.1186/1755-8794-4-70]

24 **Cecchini MJ**, Hosein K, Howlett CJ, Joseph M, Mura M. Comprehensive gene expression profiling identifies distinct and overlapping transcriptional profiles in non-specific interstitial pneumonia and idiopathic pulmonary fibrosis. *Respir Res* 2018; **19**: 153 [PMID: 30111332 DOI: 10.1186/s12931-018-0857-1]

25 **Davis S**, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. *Bioinformatics* 2007; **23**: 1846-1847 [PMID: 17496320 DOI: 10.1093/bioinformatics/btm254]

26 **Ritchie ME**, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015; **43**: e47 [PMID: 25605792 DOI: 10.1093/nar/gkv007]

27 **Gao CH**, Yu G, Cai P. ggVennDiagram: An Intuitive, Easy-to-Use, and Highly Customizable R Package to Generate Venn Diagram. *Front Genet* 2021; **12**: 706907 [PMID: 34557218 DOI: 10.3389/fgene.2021.706907]

28 **Yu G**, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 2012; **16**: 284-287 [PMID: 22455463 DOI: 10.1089/omi.2011.0118]

29 **Sherman BT**, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Res* 2022; **50**: W216-W221 [PMID: 35325185 DOI: 10.1093/nar/gkac194]

30 **Bader GD**, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. *BMC Bioinformatics* 2003; **4**: 2 [PMID: 12525261 DOI: 10.1186/1471-2105-4-2]

31 **Chin CH**, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 2014; **8 Suppl 4**: S11 [PMID: 25521941 DOI: 10.1186/1752-0509-8-S4-S11]

32 **Prasse A**, Binder H, Schupp JC, Kayser G, Bargagli E, Jaeger B, Hess M, Rittinghausen S, Vuga L, Lynn H, Violette S, Jung B, Quast K, Vanaudenaerde B, Xu Y, Hohlfeld JM, Krug N, Herazo-Maya JD, Rottoli P, Wuyts WA, Kaminski N. BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2019; **199**: 622-630 [PMID: 30141961 DOI: 10.1164/rccm.201712-2551OC]

33 **Wickham H**. ggplot2: Elegant Graphics for Data Analysis. 2nd ed. 2016. Cham: Springer International Publishing: Imprint: Springer, 2016

34 **Borges LF**, Jagadeesan V, Goldberg H, Gavini S, Lo WK, Burakoff R, Feldman N, Chan WW. Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis. *J Neurogastroenterol Motil* 2018; **24**: 395-402 [PMID: 29969857 DOI: 10.5056/jnm18023]

35 **Salisbury ML**, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, Wells AU, Schmidt SL, Martinez FJ, Flaherty KR. Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. *Chest* 2016; **149**: 491-498 [PMID: 26425858 DOI: 10.1378/chest.15-0530]

36 **Tong Z**, Cui Q, Wang J, Zhou Y. TransmiR v2.0: an updated transcription factor-microRNA regulation database. *Nucleic Acids Res* 2019; **47**: D253-D258 [PMID: 30371815 DOI: 10.1093/nar/gky1023]

37 **Zehender A**, Huang J, Györfi AH, Matei AE, Trinh-Minh T, Xu X, Li YN, Chen CW, Lin J, Dees C, Beyer C, Gelse K, Zhang ZY, Bergmann C, Ramming A, Birchmeier W, Distler O, Schett G, Distler JHW. The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis. *Nat Commun* 2018; **9**: 3259 [PMID: 30108215 DOI: 10.1038/s41467-018-05768-3]

38 **Zhao Y**, Sun J, Li Y, Zhou X, Zhai W, Wu Y, Chen G, Gou S, Sui X, Zhao W, Qiu L, Yao Y, Sun Y, Chen C, Qi Y, Gao Y. Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression *via* AKT/GSK3β/IL-8 signaling pathway. *Acta Pharm Sin B* 2021; **11**: 2835-2849 [PMID: 34589400 DOI: 10.1016/j.apsb.2021.03.009]

39 **Cai C**, Zeng Q, Zhou G, Mu X. Identification of novel transcription factor-microRNA-mRNA co-regulatory networks in pulmonary large-cell neuroendocrine carcinoma. *Ann Transl Med* 2021; **9**: 133 [PMID: 33569435 DOI: 10.21037/atm-20-7759]

40 **Shalgi R**, Lieber D, Oren M, Pilpel Y. Global and local architecture of the mammalian microRNA-transcription factor regulatory network. *PLoS Comput Biol* 2007; **3**: e131 [PMID: 17630826 DOI: 10.1371/journal.pcbi.0030131]

41 **Zhang HM**, Kuang S, Xiong X, Gao T, Liu C, Guo AY. Transcription factor and microRNA co-regulatory loops: important regulatory motifs in biological processes and diseases. *Brief Bioinform* 2015; **16**: 45-58 [PMID: 24307685 DOI: 10.1093/bib/bbt085]

42 **Cui H**, Xie N, Banerjee S, Dey T, Liu RM, Antony VB, Sanders YY, Adams TS, Gomez JL, Thannickal VJ, Kaminski N, Liu G. CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging. *Am J Respir Crit Care Med* 2022; **206**: 459-475 [PMID: 35687485 DOI: 10.1164/rccm.202109-2151OC]

43 **Yao Y**, Li Z, Gao W. Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and NSCLC Progression:Evidence From Bioinformatics Analysis. *Front Genet* 2022; **13**: 855789 [PMID: 35480306 DOI: 10.3389/fgene.2022.855789]

44 **George PM**, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. *Lancet Respir Med* 2019; **7**: 271-282 [PMID: 30738856 DOI: 10.1016/S2213-2600(18)30502-2]

45 **Lai JP**, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. *Gastroenterology* 2006; **130**: 2130-2144 [PMID: 16762634 DOI: 10.1053/j.gastro.2006.02.056]

46 **Sanders YY,** Zhang X, Liu H, Thannickal VJ. HDAC Inhibitor Down-Regulates COL3A1 Expression In Primary IPF Lung Fibroblasts. In: B65. Epigenetic regulation of lung cell function. American Thoracic Society, 2012: A3477–A3477

47 **Liu H**, Lei C, He Q, Pan Z, Xiao D, Tao Y. Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. *Mol Cancer* 2018; **17**: 64 [PMID: 29471827 DOI: 10.1186/s12943-018-0765-5]

48 **Seitz H**. Issues in current microRNA target identification methods. *RNA Biol* 2017; **14**: 831-834 [PMID: 28430005 DOI: 10.1080/15476286.2017.1320469]

49 **Kusko RL**, Brothers JF 2nd, Tedrow J, Pandit K, Huleihel L, Perdomo C, Liu G, Juan-Guardela B, Kass D, Zhang S, Lenburg M, Martinez F, Quackenbush J, Sciurba F, Limper A, Geraci M, Yang I, Schwartz DA, Beane J, Spira A, Kaminski N. Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2016; **194**: 948-960 [PMID: 27104832 DOI: 10.1164/rccm.201510-2026OC]

50 **Williams LM**, McCann FE, Cabrita MA, Layton T, Cribbs A, Knezevic B, Fang H, Knight J, Zhang M, Fischer R, Bonham S, Steenbeek LM, Yang N, Sood M, Bainbridge C, Warwick D, Harry L, Davidson D, Xie W, Sundstrӧm M, Feldmann M, Nanchahal J. Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300. *Proc Natl Acad Sci U S A* 2020; **117**: 20753-20763 [PMID: 32759223 DOI: 10.1073/pnas.2004281117]

51 **Cabrera S**, Maciel M, Herrera I, Nava T, Vergara F, Gaxiola M, López-Otín C, Selman M, Pardo A. Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis. *Autophagy* 2015; **11**: 670-684 [PMID: 25906080 DOI: 10.1080/15548627.2015.1034409]

52 **Caporarello N**, Lee J, Pham TX, Jones DL, Guan J, Link PA, Meridew JA, Marden G, Yamashita T, Osborne CA, Bhagwate AV, Huang SK, Nicosia RF, Tschumperlin DJ, Trojanowska M, Ligresti G. Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis. *Nat Commun* 2022; **13**: 4170 [PMID: 35879310 DOI: 10.1038/s41467-022-31890-4]

53 **Habermann AC**, Gutierrez AJ, Bui LT, Yahn SL, Winters NI, Calvi CL, Peter L, Chung MI, Taylor CJ, Jetter C, Raju L, Roberson J, Ding G, Wood L, Sucre JMS, Richmond BW, Serezani AP, McDonnell WJ, Mallal SB, Bacchetta MJ, Loyd JE, Shaver CM, Ware LB, Bremner R, Walia R, Blackwell TS, Banovich NE, Kropski JA. Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. *Sci Adv* 2020; **6**: eaba1972 [PMID: 32832598 DOI: 10.1126/sciadv.aba1972]

54 **Reyfman PA**, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S, Fernandez R, Akbarpour M, Chen CI, Ren Z, Verma R, Abdala-Valencia H, Nam K, Chi M, Han S, Gonzalez-Gonzalez FJ, Soberanes S, Watanabe S, Williams KJN, Flozak AS, Nicholson TT, Morgan VK, Winter DR, Hinchcliff M, Hrusch CL, Guzy RD, Bonham CA, Sperling AI, Bag R, Hamanaka RB, Mutlu GM, Yeldandi AV, Marshall SA, Shilatifard A, Amaral LAN, Perlman H, Sznajder JI, Argento AC, Gillespie CT, Dematte J, Jain M, Singer BD, Ridge KM, Lam AP, Bharat A, Bhorade SM, Gottardi CJ, Budinger GRS, Misharin AV. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2019; **199**: 1517-1536 [PMID: 30554520 DOI: 10.1164/rccm.201712-2410OC]

55 **Zhao L**, Wang B, Yang C, Lin Y, Zhang Z, Wang S, Ye Y, Shen Z. TDO2 knockdown inhibits colorectal cancer progression *via* TDO2-KYNU-AhR pathway. *Gene* 2021; **792**: 145736 [PMID: 34051337 DOI: 10.1016/j.gene.2021.145736]

56 **Hu S**, Lu H, Xie W, Wang D, Shan Z, Xing X, Wang XM, Fang J, Dong W, Dai W, Guo J, Zhang Y, Wen S, Guo XY, Chen Q, Bai F, Wang Z. TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. *J Clin Invest* 2022; **132** [PMID: 35972800 DOI: 10.1172/JCI157649]

**Footnotes**

**Institutional review board statement:** Our manuscript involves experiments on mice, as well as the A549 and IMR-90 cell lines, but does not involve any human experimentation.

**Institutional animal care and use committee statement:** The study was reviewed and approved by the Experimental Animal Ethics Committee of Henan University of Chinese Medicine, No. DWLLGZR202202036.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** The authors confirm that the data supporting the findings of this study are available.

**ARRIVE guidelines statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 14, 2023

**First decision:** May 17, 2023

**Article in press:**

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Brody AR, United States; Jaing TH, Taiwan **S-Editor:** Fan JR **L-Editor:** A **P-Editor:**


**Figure Legends**




**Figure 1 Identification and enrichment analysis of differentially expressed genes in idiopathic pulmonary fibrosis data compared with control data.** A: Analysis of common differentially expressed genes was performed between idiopathic pulmonary fibrosis and normal lung tissues with thresholds of *P* < 0.05 and fold change > 1.5 based on GSE53845, GSE47460 (GPL14550 and GPL6480), and GSE24206; B-D: Three categories of Gene Ontology analysis: Biological processes, cell components, and molecular functions; E: Kyoto Encyclopedia of Genes and Genomes and Reactome pathway analysis.




**Figure 2 Hub genes identified by maximum neighbourhood component, Degree, density of maximum neighbourhood component, maximal clique centrality, edge percolated component, venn diagram of hub genes.** A: Maximum neighbourhood component; B: Degree; C: Density of maximum neighbourhood component; D: Maximal clique centrality; E: Edge percolated component; F: Venn diagram. The 15 hub genes were *RET*, *TGFB3*, *HSD17B6*, *SULF1*, *ASPN*, *SDR16C5*, *ALDH1A3*, *COL3A1*, *COL1A2*, *KCNMA1*, *COL5A2*, *KCNMB4*, *AOX1*, *KCNN3*, and *KCNN4*.




**Figure 3 Correlations between lung gene expression and forced vital capacity and diffusing capacity.** A-M: *TDO2*, *RET*, *TGFB3*, *SULF1*, *ASPN*, *ALDH1A3*, *COL3A1*, *COL1A2*, *KCNMA1*, *COL5A2*, *KCNN3*, *KCNN4* and *AOX1* expression was negatively correlated with diffusing capacity of carbon monoxide (DLCO); N-P: *HSD17B6*, *SDR16C5*, and *KCNMB4* were significantly positively correlated with DLCO. The Pearson correlation metric was computed by using the ‘stat\_cor’ function in R. DLCO: Diffusing capacity of carbon monoxide.




**Figure 4 Survival analysis of overlapping hub genes.** Overall survival curves show that higher expression of *TDO2*, *HSD17B6*, *SULF1*, *SDR16C5*, *COL3A1*, *KCNMA1*, *KCNMB4*, *KCNN4* and *ALADH1A3* is associated with a worse survival rate. A: *TDO2*; B: *HSD17B6*; C: *SULF1*; D: *SDR16C5*; E: *COL3A1*; F: *KCNMA1*; G: *KCNMB4*; H: *KCNN4*; I: *ALADH1A3*.




**Figure 5 mRNA expression levels of *TDO2*, *COL3A1*, *KCNN4*, *SULF1*, *HSD17B6*, *KCNMA1*, *KCNMB4*, *ALDH1A3*, and *SDR16C5* in the lung tissue *vs* PBS (*n* = 5 for PBS group, *n* = 5 for Bleo group).** The statistical test used was the t test. Data are expressed as the mean with SD. a*P* < 0.01, b*P* < 0.05.



**Figure 6 Transcription factors-miRNA-mRNA regulatory network.** Transcription factors, miRNA, and mRNA are represented by hexagons, circles, and diamonds, respectively.



**Figure 7 *TDO2* increased in Idiopathic pulmonary fibrosis and was validated in scRNA-seq data.** A: Upregulation of *TDO2* in Idiopathic pulmonary fibrosis of trained data (*e.g.*, in GSE47460). The statistical test used was the t test; B and C: Correlations between lung *TDO2* expression and diffusing capacity of carbon monoxide (B) and forced vital capacity (C) in GSE47460. The Pearson correlation metric was computed by using the ‘stat\_cor’ function in R; D: UMAP of 8,942 randomly selected resident lung parenchymal cells from GSE136831; E: UMAP with cells labelled by normalized *TDO2* expression; F: Differential gene expression analysis using the log-fold change expression *vs* the difference in the percentage of cells expressing the gene comparing alveolar fibroblast cluster *vs* other cluster cells (Δ Percentage Difference). Labelled genes have a log2-fold change > 1, Δ Percentage Difference > 20% and adjusted *P* value from Wilcoxon rank sum test < 0.05. DLCO: Diffusing capacity of carbon monoxide; IPF: Idiopathic pulmonary fibrosis; FVC: Forced vital capacity.



**Figure 8 Western blot analysis of α-smooth muscle actin and COL-1 in A549, MLE-12, and IMR-90 cells.** Western blot quantification results in A549, MLE-12 and IMR-90 cells. A and D: A549; B and E: MLE-12; C and F: IMR-90. In line with the homogeneity of variance, the least significance difference method was used when assuming homogeneity of variance. a*P* < 0.01 *vs* phosphate-buffered saline; b*P* < 0.05 *vs* transforming growth factor-β. PBS: Phosphate-buffered saline; α-SMA: α-smooth muscle actin; TGF-β: Transforming growth factor-β.

**Table 1 Primer sequences**

|  |  |  |
| --- | --- | --- |
| **Gene name** | **Forward** | **Reverse** |
| *TDO2* | AACATGCTCAAGGTGATAGCTC | GAACCGAGAACTGCTGTACCA |
| *SULF1* | TGTGTTCCACCGTTCGGTC | CACATCCTGGTCGTCAGTGAG |
| *KCNN4* | GCTCAACCAAGTCCGCTTC | GTGATCGGAATCAGCCACAGT |
| *COL3A1* | CTGTAACATGGAAACTGGGGAAA | CCATAGCTGAACTGAAAACCACC |
| *HSD17B6* | GGAGCGTGTTGGAGACAGAG | GAGGTTCACTTGAAAGATAGGCA |
| *KCNMA1* | TCACGGAACTCGCTAAGCC | AATGTGCGTCCCACTGTTTTT |
| *KCNMB4* | ACCAACCCCAAGTGCTCCTAT | GAATGGCTGGGAACCGATCTC |
| *ALDH1A3* | ATCAACAACGACTGGCACGAA | CACATCGGGCTTATCTCCTTC |
| *SDR16C5* | TTGAGTGTTTTGGAGGCCCTA | AACTGCAATGCTAAGAGCCTT |
| *18S* | GTAACCCGTTGAACCCCATT | CCATCCAATCGGTAGTAGCG |